Trial reportCerebrovascular diseases (Basel, Switzerland)2016
Pre-Stroke Use of Beta-Blockers Does Not Lower Post-Stroke Infection Rate: An Exploratory Analysis of the Preventive Antibiotics in Stroke Study.
Trial report in Cerebrovascular diseases (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Immunomodulation for stroke-associated pneumonia: a systematic review of mechanistic insight and emerging therapeutic strategies in animal models.Frontiers in immunology · 2026Pooled it
- A systematic review and meta-analysis show a decreasing prevalence of post-stroke infections.BMC neurology · 2024Pooled it
- Pooled it
- The active role of pulmonary immunity in ischaemic stroke.Journal of neuroinflammation · 2026Review
- Impact of Beta-Blockers on Pneumonia, Mortality and Functional Outcomes of Patients with Intracerebral Hemorrhage-A Retrospective Multicenter Study.Journal of inflammation research · 2025Article
- A prospective observational study of estimating drug related problems and clinical outcomes in subtypes of stroke patients.PloS one · 2024Observational
- Role of the gut microbiota in complications after ischemic stroke.Frontiers in cellular and infection microbiology · 2024Review
- Association between Antihypertensive Therapy and Risk of Acute Lower Respiratory Infections (ALRI): A Retrospective Cohort Study.Healthcare (Basel, Switzerland) · 2022Article
- Systemic inflammation after stroke: implications for post-stroke comorbidities.EMBO molecular medicine · 2022Review
- The role of βBrain, behavior, & immunity - health · 2021Article
- Brain to periphery in acute ischemic stroke: Mechanisms and clinical significance.Frontiers in neuroendocrinology · 2021Review
- Effect of Beta-Blockers on Stroke Outcome: A Meta-Analysis.Clinical epidemiology · 2021Review
- Beyond the Brain: The Systemic Pathophysiological Response to Acute Ischemic Stroke.Journal of stroke · 2020Review
- Hospital-Level Variations in Rates of Inpatient Urinary Tract Infections in Stroke.Frontiers in neurology · 2019Article
- Old Dog New Tricks; Revisiting How Stroke Modulates the Systemic Immune Landscape.Frontiers in neurology · 2019Review
- Immunomodulatory Therapeutic Strategies in Stroke.Frontiers in pharmacology · 2019Review
- Pre admission treatment with Beta-blockers in hypertensive patients with acute stroke and 3-month outcome-Data from a national stroke registry.Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
- Lymphocyte-to-monocyte ratio on day 7 is associated with outcomes in acute ischemic stroke.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018Article
- Influence of beta-blocker therapy on the risk of infections and death in patients at high risk for stroke induced immunodepression.PloS one · 2018Article
- Increased infections with β-blocker use in ischemic stroke, a βNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundStroke-associated infections occur frequently and are associated with unfavorable outcome. Previous cohort studies suggest a protective effect of beta-blockers (BBs) against infections. A sympathetic drive may increase immune suppression and infections.
aimThis study is aimed at investigating the association between BB treatment at baseline and post-stroke infection in the Preventive Antibiotics in Stroke Study (PASS), a prospective clinical trial.
methodsWe performed an exploratory analysis in PASS, 2,538 patients with acute phase of stroke (24 h after onset) were randomized to ceftriaxone (intravenous, 2 g per day for 4 days) in addition to stroke unit care, or standard stroke unit care without preventive antibiotic treatment. All clinical data, including use of BBs, was prospectively collected. Infection was diagnosed by the treating physician, and independently by an expert panel blinded for all other data. Multivariable analysis was performed to investigate the relation between BB treatment and infection rate.
resultsInfection, as defined by the physician, occurred in 348 of 2,538 patients (14%). Multivariable analysis showed that the use of BBs at baseline was associated with the development of infection during clinical course (adjusted OR (aOR) 1.61, 95% CI 1.19-2.18; p < 0.01). BB use at baseline was also associated with the development of pneumonia (aOR 1.56, 95% CI 1.05-2.30; p = 0.03). Baseline BB use was not associated with mortality (aOR 1.14, 95% CI 0.84-1.53; p = 0.41) or unfavorable outcome at 3 months (aOR 1.10, 95% CI 0.89-1.35; p = 0.39).
conclusionsPatients treated with BBs prior to stroke have a higher rate of infection and pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.